Reviva Pharmaceuticals Holdings, Inc. has entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Alliance Global Partners. This agreement allows Reviva to offer and sell shares of its common stock, with a total value of up to $50 million, through an at-the-market offering program. The shares will be sold at the company's discretion, leveraging the agents' commercially reasonable efforts to facilitate the sales. The offering will be conducted under the company's shelf Registration Statement filed with the SEC, with an effective registration date in February 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.